Puhr, Hannah C. http://orcid.org/0000-0002-7203-8732
Weirauch, Clemens C.
Selimi, Flora
Oberreiter, Karin
Dieterle, Martin A.
Jomrich, Gerd
Schoppmann, Sebastian F.
Prager, Gerald W. http://orcid.org/0000-0002-7854-7781
Berghoff, Anna S. http://orcid.org/0000-0001-9379-6797
Preusser, Matthias http://orcid.org/0000-0003-3541-2315
Ilhan-Mutlu, Aysegül http://orcid.org/0000-0001-8291-0873
Funding for this research was provided by:
Medical University of Vienna
Article History
Received: 22 August 2023
Accepted: 12 September 2023
First Online: 26 September 2023
Declarations
:
: HC.P. has received travel support from Eli Lilly, MSD, Novartis, Pfizer, Pierre Fabre and Roche and received lecture honoraria from Eli Lilly. A.I-M.: Participation in advisory boards organised by MSD, Servier, Daiichi Sankyo and BMS, Lecture honoraria from Eli Lilly, Servier, BMS, MSD, Astellas and Daiichi Sankyo, Local PI for clinical trials sponsored by BMS and Roche, Consulting for Astellas and MSD, Travel support from BMS, Roche, Eli Lilly and Daiichi Sankyo. M.P. has received honoraria for lectures, consultation or advisory board participation from the following for-profit companies: Bayer, Bristol-Myers Squibb, Novartis, Gerson Lehrman Group (GLG), CMC Contrast, GlaxoSmithKline, Mundipharma, Roche, BMJ Journals, MedMedia, Astra Zeneca, AbbVie, Lilly, Medahead, Daiichi Sankyo, Sanofi, Merck Sharp & Dome, Tocagen, Adastra, Gan & Lee Pharmaceuticals, Servier. ASB has research support from Daiichi Sankyo and Roche, honoraria for lectures, consultation or advisory board participation from Roche, Bristol-Meyers Squibb, Merck, Daiichi Sankyo; as well as travel support from Roche, Amgen, Daiichi Sankyo, and AbbVie. GW.P. has the following to declare: Advisory Role/Speaker's Fee: Merck Serono, Roche, Amgen, Sanofi, Lilly, Servier, Taiho, Bayer, Halozyme, BMS, MSD, Celgene, Pierre Fabre, Shire, CECOG, Astra Zeneca. All other authors declare no conflict of interest.
: Due to the retrospective design, no separate informed consent was necessary in the scope of this study. This is in line with local ethical standards and was approved by the ethics committee of the Medical University of Vienna (reference number: 1600/2021).
: This study was performed within the PhD thesis of Hannah Christina Puhr with the title “Immunological, genetic and prognostic factors related to outcome in patients with upper gastrointestinal tract cancer” in the Doctoral Program N790 “Clinical & Experimental Oncology” at the Medical University of Vienna. Parts of this analysis were presented as a poster at the World Congress of Gastrointestinal Cancer 2021 (June 30–July 3, 2021) and the first author HC.P. was awarded a “young investigator award” for the work.
: All procedures were in accordance with the ethical standards of the responsible committee on human experimentation and with the Helsinki Declaration of 1964 and latter versions. The study was approved by the ethics committee of the Medical University of Vienna (reference number: 1600/2021). The risk of publication of sensitive patient data was minimised by restrictions of data accession and pseudonymized statistical analysis.